{"entity":{"type":"insider","cik":"0001645157","url":"/insider/0001645157","json_url":"/insider/0001645157.json","name":"Foresite Capital Management III, LLC","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":32,"n_filings":13,"first":"2015-08-11","last":"2020-03-02","span_basis":"filed_date"},"name_variants":[{"name":"Foresite Capital Management III, LLC","source":"filing","n_filings":13,"first_seen":"2015-08-11","last_seen":"2020-03-02"}],"transactions":[{"id":2138464,"accession":"0001209191-20-014562","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-20-014562","line_url":"/filing/0001209191-20-014562","is_derivative":false,"issuer_cik":"0001337553","issuer_name":"AERIE PHARMACEUTICALS INC","issuer_ticker":"AERI","issuer_name_source":null,"issuer_url":"/issuer/0001337553","owner_cik":null,"owner_name":"Foresite Capital Fund IV, L.P.; Tananbaum James B.; Foresite Capital Management III, LLC; Foresite Capital Management IV, LLC; Foresite Capital Fund III, L.P.; Foresite Capital Management II, LLC; Foresite Capital Fund II, L.P.","owner_display_name":"Foresite Capital Fund IV, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000000.0,"shares_display":"1,000,000","price_per_share":17.07,"price_display":"17.07","price_state":"stated","total_value":17070000.0,"total_display":"17,070,000.00","total_whole":"17,070,000","shares_owned_after":1925020.0,"shares_owned_after_display":"1,925,020","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-02-27","filed_date":"2020-03-02","scope":"insider","n_lines":3},{"id":8120795,"accession":"0001209191-19-048830","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-19-048830","line_url":"/filing/0001209191-19-048830#line-3","is_derivative":false,"issuer_cik":"0001337553","issuer_name":"AERIE PHARMACEUTICALS INC","issuer_ticker":"AERI","issuer_name_source":null,"issuer_url":"/issuer/0001337553","owner_cik":null,"owner_name":"Tananbaum James B.; Foresite Capital Fund IV, L.P.; Foresite Capital Management II, LLC; Foresite Capital Fund II, L.P.; Foresite Capital Fund III, L.P.; Foresite Capital Management III, LLC; Foresite Capital Management IV, LLC","owner_display_name":"Tananbaum James B.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":15700.0,"shares_display":"15,700","price_per_share":18.42,"price_display":"18.42","price_state":"stated","total_value":289194.0,"total_display":"289,194.00","total_whole":"289,194","shares_owned_after":2350477.0,"shares_owned_after_display":"2,350,477","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-09-05","filed_date":"2019-09-06","scope":"insider"},{"id":8120792,"accession":"0001209191-19-048830","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-048830","line_url":"/filing/0001209191-19-048830","is_derivative":false,"issuer_cik":"0001337553","issuer_name":"AERIE PHARMACEUTICALS INC","issuer_ticker":"AERI","issuer_name_source":null,"issuer_url":"/issuer/0001337553","owner_cik":null,"owner_name":"Tananbaum James B.; Foresite Capital Fund IV, L.P.; Foresite Capital Management II, LLC; Foresite Capital Fund II, L.P.; Foresite Capital Fund III, L.P.; Foresite Capital Management III, LLC; Foresite Capital Management IV, LLC","owner_display_name":"Tananbaum James B.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":100200.0,"shares_display":"100,200","price_per_share":18.48,"price_display":"18.48","price_state":"stated","total_value":1851696.0,"total_display":"1,851,696.00","total_whole":"1,851,696","shares_owned_after":1400900.0,"shares_owned_after_display":"1,400,900","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-09-04","filed_date":"2019-09-06","scope":"insider","n_lines":2},{"id":8102225,"accession":"0001209191-19-048394","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-19-048394","line_url":"/filing/0001209191-19-048394","is_derivative":false,"issuer_cik":"0001337553","issuer_name":"AERIE PHARMACEUTICALS INC","issuer_ticker":"AERI","issuer_name_source":null,"issuer_url":"/issuer/0001337553","owner_cik":null,"owner_name":"Foresite Capital Fund IV, L.P.; Foresite Capital Management III, LLC; Foresite Capital Management IV, LLC; Foresite Capital Management II, LLC; Foresite Capital Fund II, L.P.; Foresite Capital Fund III, L.P.; Tananbaum James B.","owner_display_name":"Foresite Capital Fund IV, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":50000.0,"shares_display":"50,000","price_per_share":20.81482,"price_display":"20.81","price_state":"stated","total_value":1040741.0,"total_display":"1,040,741.00","total_whole":"1,040,741","shares_owned_after":2310377.0,"shares_owned_after_display":"2,310,377","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-09-03","filed_date":"2019-09-04","scope":"insider","n_lines":2},{"id":8102213,"accession":"0001209191-19-048394","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-19-048394","line_url":"/filing/0001209191-19-048394#line-1","is_derivative":false,"issuer_cik":"0001337553","issuer_name":"AERIE PHARMACEUTICALS INC","issuer_ticker":"AERI","issuer_name_source":null,"issuer_url":"/issuer/0001337553","owner_cik":null,"owner_name":"Foresite Capital Fund IV, L.P.; Foresite Capital Management III, LLC; Foresite Capital Management IV, LLC; Foresite Capital Management II, LLC; Foresite Capital Fund II, L.P.; Foresite Capital Fund III, L.P.; Tananbaum James B.","owner_display_name":"Foresite Capital Fund IV, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":25000.0,"shares_display":"25,000","price_per_share":21.36,"price_display":"21.36","price_state":"stated","total_value":534000.0,"total_display":"534,000.00","total_whole":"534,000","shares_owned_after":2275477.0,"shares_owned_after_display":"2,275,477","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-08-30","filed_date":"2019-09-04","scope":"insider"},{"id":8027908,"accession":"0001209191-19-047387","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-19-047387","line_url":"/filing/0001209191-19-047387#line-3","is_derivative":false,"issuer_cik":"0001337553","issuer_name":"AERIE PHARMACEUTICALS INC","issuer_ticker":"AERI","issuer_name_source":null,"issuer_url":"/issuer/0001337553","owner_cik":null,"owner_name":"Tananbaum James B.; Foresite Capital Fund IV, L.P.; Foresite Capital Management III, LLC; Foresite Capital Management IV, LLC; Foresite Capital Fund II, L.P.; Foresite Capital Fund III, L.P.; Foresite Capital Management II, LLC","owner_display_name":"Tananbaum James B.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":38300.0,"shares_display":"38,300","price_per_share":23.42,"price_display":"23.42","price_state":"stated","total_value":896986.0,"total_display":"896,986.00","total_whole":"896,986","shares_owned_after":2250477.0,"shares_owned_after_display":"2,250,477","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-08-23","filed_date":"2019-08-23","scope":"insider"},{"id":8027907,"accession":"0001209191-19-047387","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-047387","line_url":"/filing/0001209191-19-047387#line-2","is_derivative":false,"issuer_cik":"0001337553","issuer_name":"AERIE PHARMACEUTICALS INC","issuer_ticker":"AERI","issuer_name_source":null,"issuer_url":"/issuer/0001337553","owner_cik":null,"owner_name":"Tananbaum James B.; Foresite Capital Fund IV, L.P.; Foresite Capital Management III, LLC; Foresite Capital Management IV, LLC; Foresite Capital Fund II, L.P.; Foresite Capital Fund III, L.P.; Foresite Capital Management II, LLC","owner_display_name":"Tananbaum James B.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6700.0,"shares_display":"6,700","price_per_share":23.68,"price_display":"23.68","price_state":"stated","total_value":158656.0,"total_display":"158,656.00","total_whole":"158,656","shares_owned_after":2212177.0,"shares_owned_after_display":"2,212,177","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-08-22","filed_date":"2019-08-23","scope":"insider"},{"id":8027902,"accession":"0001209191-19-047387","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-19-047387","line_url":"/filing/0001209191-19-047387#line-1","is_derivative":false,"issuer_cik":"0001337553","issuer_name":"AERIE PHARMACEUTICALS INC","issuer_ticker":"AERI","issuer_name_source":null,"issuer_url":"/issuer/0001337553","owner_cik":null,"owner_name":"Tananbaum James B.; Foresite Capital Fund IV, L.P.; Foresite Capital Management III, LLC; Foresite Capital Management IV, LLC; Foresite Capital Fund II, L.P.; Foresite Capital Fund III, L.P.; Foresite Capital Management II, LLC","owner_display_name":"Tananbaum James B.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1153.0,"shares_display":"1,153","price_per_share":23.25,"price_display":"23.25","price_state":"stated","total_value":26807.25,"total_display":"26,807.25","total_whole":"26,807","shares_owned_after":2205477.0,"shares_owned_after_display":"2,205,477","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-08-21","filed_date":"2019-08-23","scope":"insider"},{"id":8120433,"accession":"0001209191-19-046913","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-19-046913","line_url":"/filing/0001209191-19-046913#line-3","is_derivative":false,"issuer_cik":"0001337553","issuer_name":"AERIE PHARMACEUTICALS INC","issuer_ticker":"AERI","issuer_name_source":null,"issuer_url":"/issuer/0001337553","owner_cik":null,"owner_name":"Foresite Capital Management III, LLC; Foresite Capital Management IV, LLC; Foresite Capital Management II, LLC; Tananbaum James B.; Foresite Capital Fund IV, L.P.; Foresite Capital Fund II, L.P.; Foresite Capital Fund III, L.P.","owner_display_name":"Foresite Capital Management III, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":50000.0,"shares_display":"50,000","price_per_share":23.21,"price_display":"23.21","price_state":"stated","total_value":1160500.0,"total_display":"1,160,500.00","total_whole":"1,160,500","shares_owned_after":2204324.0,"shares_owned_after_display":"2,204,324","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-08-20","filed_date":"2019-08-20","scope":"insider"},{"id":8120430,"accession":"0001209191-19-046913","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-046913","line_url":"/filing/0001209191-19-046913#line-2","is_derivative":false,"issuer_cik":"0001337553","issuer_name":"AERIE PHARMACEUTICALS INC","issuer_ticker":"AERI","issuer_name_source":null,"issuer_url":"/issuer/0001337553","owner_cik":null,"owner_name":"Foresite Capital Management III, LLC; Foresite Capital Management IV, LLC; Foresite Capital Management II, LLC; Tananbaum James B.; Foresite Capital Fund IV, L.P.; Foresite Capital Fund II, L.P.; Foresite Capital Fund III, L.P.","owner_display_name":"Foresite Capital Management III, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3847.0,"shares_display":"3,847","price_per_share":23.34,"price_display":"23.34","price_state":"stated","total_value":89788.98,"total_display":"89,788.98","total_whole":"89,789","shares_owned_after":2154324.0,"shares_owned_after_display":"2,154,324","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-08-19","filed_date":"2019-08-20","scope":"insider"},{"id":8120427,"accession":"0001209191-19-046913","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-19-046913","line_url":"/filing/0001209191-19-046913#line-1","is_derivative":false,"issuer_cik":"0001337553","issuer_name":"AERIE PHARMACEUTICALS INC","issuer_ticker":"AERI","issuer_name_source":null,"issuer_url":"/issuer/0001337553","owner_cik":null,"owner_name":"Foresite Capital Management III, LLC; Foresite Capital Management IV, LLC; Foresite Capital Management II, LLC; Tananbaum James B.; Foresite Capital Fund IV, L.P.; Foresite Capital Fund II, L.P.; Foresite Capital Fund III, L.P.","owner_display_name":"Foresite Capital Management III, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":100000.0,"shares_display":"100,000","price_per_share":24.23,"price_display":"24.23","price_state":"stated","total_value":2423000.0,"total_display":"2,423,000.00","total_whole":"2,423,000","shares_owned_after":2150477.0,"shares_owned_after_display":"2,150,477","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-08-16","filed_date":"2019-08-20","scope":"insider"},{"id":8568332,"accession":"0001209191-19-046012","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-19-046012","line_url":"/filing/0001209191-19-046012#line-4","is_derivative":false,"issuer_cik":"0001337553","issuer_name":"AERIE PHARMACEUTICALS INC","issuer_ticker":"AERI","issuer_name_source":null,"issuer_url":"/issuer/0001337553","owner_cik":null,"owner_name":"Tananbaum James B.; Foresite Capital Fund II, L.P.; Foresite Capital Fund IV, L.P.; Foresite Capital Management III, LLC; Foresite Capital Management IV, LLC; Foresite Capital Fund III, L.P.; Foresite Capital Management II, LLC","owner_display_name":"Tananbaum James B.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":100000.0,"shares_display":"100,000","price_per_share":23.73,"price_display":"23.73","price_state":"stated","total_value":2373000.0,"total_display":"2,373,000.00","total_whole":"2,373,000","shares_owned_after":2050477.0,"shares_owned_after_display":"2,050,477","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-08-14","filed_date":"2019-08-14","scope":"insider"},{"id":8568328,"accession":"0001209191-19-046012","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-19-046012","line_url":"/filing/0001209191-19-046012","is_derivative":false,"issuer_cik":"0001337553","issuer_name":"AERIE PHARMACEUTICALS INC","issuer_ticker":"AERI","issuer_name_source":null,"issuer_url":"/issuer/0001337553","owner_cik":null,"owner_name":"Tananbaum James B.; Foresite Capital Fund II, L.P.; Foresite Capital Fund IV, L.P.; Foresite Capital Management III, LLC; Foresite Capital Management IV, LLC; Foresite Capital Fund III, L.P.; Foresite Capital Management II, LLC","owner_display_name":"Tananbaum James B.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":250000.0,"shares_display":"250,000","price_per_share":25.3493672,"price_display":"25.35","price_state":"stated","total_value":6337341.8,"total_display":"6,337,341.80","total_whole":"6,337,342","shares_owned_after":1310000.0,"shares_owned_after_display":"1,310,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-08-13","filed_date":"2019-08-14","scope":"insider","n_lines":2},{"id":8568322,"accession":"0001209191-19-046012","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-19-046012","line_url":"/filing/0001209191-19-046012#line-1","is_derivative":false,"issuer_cik":"0001337553","issuer_name":"AERIE PHARMACEUTICALS INC","issuer_ticker":"AERI","issuer_name_source":null,"issuer_url":"/issuer/0001337553","owner_cik":null,"owner_name":"Tananbaum James B.; Foresite Capital Fund II, L.P.; Foresite Capital Fund IV, L.P.; Foresite Capital Management III, LLC; Foresite Capital Management IV, LLC; Foresite Capital Fund III, L.P.; Foresite Capital Management II, LLC","owner_display_name":"Tananbaum James B.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":189555.0,"shares_display":"189,555","price_per_share":24.43,"price_display":"24.43","price_state":"stated","total_value":4630828.65,"total_display":"4,630,828.65","total_whole":"4,630,829","shares_owned_after":1060000.0,"shares_owned_after_display":"1,060,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-08-12","filed_date":"2019-08-14","scope":"insider"},{"id":4197054,"accession":"0001209191-17-036603","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-17-036603","line_url":"/filing/0001209191-17-036603","is_derivative":false,"issuer_cik":"0001337553","issuer_name":"AERIE PHARMACEUTICALS INC","issuer_ticker":"AERI","issuer_name_source":null,"issuer_url":"/issuer/0001337553","owner_cik":null,"owner_name":"Foresite Capital Management II, LLC; Tananbaum James B.; Foresite Capital Fund II, L.P.; Foresite Capital Fund III, L.P.; Foresite Capital Management III, LLC","owner_display_name":"Foresite Capital Management II, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":55.95,"price_display":"55.95","price_state":"stated","total_value":1119000.0,"total_display":"1,119,000.00","total_whole":"1,119,000","shares_owned_after":1950477.0,"shares_owned_after_display":"1,950,477","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-05-26","filed_date":"2017-05-31","scope":"insider","n_lines":2},{"id":9270141,"accession":"0001209191-16-145532","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-16-145532","line_url":"/filing/0001209191-16-145532","is_derivative":false,"issuer_cik":"0001337553","issuer_name":"AERIE PHARMACEUTICALS INC","issuer_ticker":"AERI","issuer_name_source":null,"issuer_url":"/issuer/0001337553","owner_cik":null,"owner_name":"Foresite Capital Fund II, L.P.; Foresite Capital Fund III, L.P.; Foresite Capital Management II, LLC; Foresite Capital Management III, LLC; Tananbaum James B.","owner_display_name":"Foresite Capital Fund II, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50000.0,"shares_display":"50,000","price_per_share":40.3399,"price_display":"40.34","price_state":"stated","total_value":2016995.0,"total_display":"2,016,995.00","total_whole":"2,016,995","shares_owned_after":1647901.0,"shares_owned_after_display":"1,647,901","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-10-06","filed_date":"2016-10-11","scope":"insider","n_lines":2},{"id":2421758,"accession":"0001209191-16-145487","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-16-145487","line_url":"/filing/0001209191-16-145487","is_derivative":false,"issuer_cik":"0001337553","issuer_name":"AERIE PHARMACEUTICALS INC","issuer_ticker":"AERI","issuer_name_source":null,"issuer_url":"/issuer/0001337553","owner_cik":null,"owner_name":"Tananbaum James B.; Foresite Capital Management II, LLC; Foresite Capital Fund II, L.P.; Foresite Capital Fund III, L.P.; Foresite Capital Management III, LLC","owner_display_name":"Tananbaum James B.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50000.0,"shares_display":"50,000","price_per_share":40.3399,"price_display":"40.34","price_state":"stated","total_value":2016995.0,"total_display":"2,016,995.00","total_whole":"2,016,995","shares_owned_after":1672697.0,"shares_owned_after_display":"1,672,697","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-10-06","filed_date":"2016-10-07","scope":"insider","n_lines":2},{"id":2130890,"accession":"0001209191-16-133904","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-16-133904","line_url":"/filing/0001209191-16-133904#line-1","is_derivative":false,"issuer_cik":"0001337553","issuer_name":"AERIE PHARMACEUTICALS INC","issuer_ticker":"AERI","issuer_name_source":null,"issuer_url":"/issuer/0001337553","owner_cik":null,"owner_name":"Foresite Capital Fund II, L.P.; Foresite Capital Fund III, L.P.; Foresite Capital Management II, LLC; Tananbaum James B.; Foresite Capital Management III, LLC","owner_display_name":"Foresite Capital Fund II, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":250000.0,"shares_display":"250,000","price_per_share":17.5,"price_display":"17.50","price_state":"stated","total_value":4375000.0,"total_display":"4,375,000.00","total_whole":"4,375,000","shares_owned_after":1697884.0,"shares_owned_after_display":"1,697,884","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-07-22","filed_date":"2016-07-26","scope":"insider"},{"id":2414185,"accession":"0001209191-16-125229","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-16-125229","line_url":"/filing/0001209191-16-125229","is_derivative":false,"issuer_cik":"0001581754","issuer_name":"Aimmune Therapeutics, Inc.","issuer_ticker":"AIMT","issuer_name_source":null,"issuer_url":"/issuer/0001581754","owner_cik":null,"owner_name":"Foresite Capital Management II, LLC; Foresite Capital Fund III, L.P.; Foresite Capital Management III, LLC; Foresite Capital Fund II, L.P.; Tananbaum James B.","owner_display_name":"Foresite Capital Management II, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock, $0.0001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":240000.0,"shares_display":"240,000","price_per_share":15.228,"price_display":"15.23","price_state":"stated","total_value":3654720.0,"total_display":"3,654,720.00","total_whole":"3,654,720","shares_owned_after":3967900.0,"shares_owned_after_display":"3,967,900","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-05-31","filed_date":"2016-06-02","scope":"insider","n_lines":2},{"id":8848692,"accession":"0001209191-15-068040","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-15-068040","line_url":"/filing/0001209191-15-068040#line-1","is_derivative":false,"issuer_cik":"0001581754","issuer_name":"Aimmune Therapeutics, Inc.","issuer_ticker":"AIMT","issuer_name_source":null,"issuer_url":"/issuer/0001581754","owner_cik":null,"owner_name":"Foresite Capital Fund II, L.P.; Tananbaum James B.; Foresite Capital Fund III, L.P.; Foresite Capital Management II, LLC; Foresite Capital Management III, LLC","owner_display_name":"Foresite Capital Fund II, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock, $0.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":25485.0,"shares_display":"25,485","price_per_share":19.6547,"price_display":"19.65","price_state":"stated","total_value":500900.0295,"total_display":"500,900.03","total_whole":"500,900","shares_owned_after":355020.0,"shares_owned_after_display":"355,020","ownership_form":"I","is_10b5_1":null,"transaction_date":"2015-08-24","filed_date":"2015-08-26","scope":"insider"},{"id":8391485,"accession":"0000899243-15-002782","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-15-002782","line_url":"/filing/0000899243-15-002782","is_derivative":false,"issuer_cik":"0001581754","issuer_name":"Aimmune Therapeutics, Inc.","issuer_ticker":"AIMT","issuer_name_source":null,"issuer_url":"/issuer/0001581754","owner_cik":null,"owner_name":"Foresite Capital Fund II, L.P.; Tananbaum James B.; Foresite Capital Management III, LLC; Foresite Capital Management II, LLC; Foresite Capital Fund III, L.P.","owner_display_name":"Foresite Capital Fund II, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock, $0.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":642035.0,"shares_display":"642,035","price_per_share":16.119368510283707,"price_display":"16.12","price_state":"stated","total_value":10349198.7615,"total_display":"10,349,198.76","total_whole":"10,349,199","shares_owned_after":4087900.0,"shares_owned_after_display":"4,087,900","ownership_form":"I","is_10b5_1":null,"transaction_date":"2015-08-11","filed_date":"2015-08-11","scope":"insider","n_lines":3}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001337553","name":"AERIE PHARMACEUTICALS INC","url":"/issuer/0001337553","role":"Ten percent owner","n_filings":10,"first_seen":"2016-07-26","last_seen":"2020-03-02"},{"type":"issuer","type_label":"ISSUER","cik":"0001631650","name":"Aimmune Therapeutics, Inc.","url":"/issuer/0001631650","role":"Ten percent owner","n_filings":3,"first_seen":"2015-08-11","last_seen":"2016-06-02"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001645157","retrieved_at":"2026-08-23T22:59:25+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}